Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

Leukemia. 2018 Aug;32(8):1856-1860. doi: 10.1038/s41375-018-0076-2. Epub 2018 Feb 26.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Azacitidine / pharmacology*
  • Biomarkers, Tumor / genetics
  • Gene Expression Regulation, Neoplastic / drug effects
  • Granulocytes / drug effects
  • Granulocytes / metabolism
  • Granulocytes / pathology*
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / metabolism
  • Hematopoietic Stem Cells / pathology*
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology
  • Multipotent Stem Cells / drug effects
  • Multipotent Stem Cells / metabolism
  • Multipotent Stem Cells / pathology*
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / pathology
  • Pilot Projects
  • Prognosis
  • Prospective Studies

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers, Tumor
  • Azacitidine